内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

骨质疏松症：治疗的药物的非临床评价行业指南（FDA）

2019-10-31 美国食品和药品监督管理局

骨质疏松症

骨质疏松症：治疗的药物的非临床评价行业指南

中文标题：

骨质疏松症：治疗的药物的非临床评价行业指南（FDA）

英文标题：

Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry: Guidance for Industry

发布机构：

美国食品和药品监督管理局

发布日期：

2019-10-31

简要介绍：

骨质疏松症：治疗的药物的非临床评价行业指南

相关资料下载：
[AttachmentFileName(sort=100, fileName=骨质疏松症：治疗的药物的非临床评价行业指南（FDA）)] GetToolGuiderByIdResponse(projectId=1, id=cdbd91c00182223a, title=骨质疏松症：治疗的药物的非临床评价行业指南（FDA）, enTitle=Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry: Guidance for Industry, guiderFrom=, authorId=null, author=, summary=骨质疏松症：治疗的药物的非临床评价行业指南, cover=, journalId=null, articlesId=null, associationId=486, associationName=美国食品和药品监督管理局, associationIntro=美国食品和药品监督管理局是美国公共卫生及服务部的一个代理商，其由委员会办公室和4个监督核心功能理事机构组成。, copyright=0, guiderPublishedTime=Thu Oct 31 08:57:46 CST 2019, originalUrl=, linkOutUrl=, content=骨质疏松症：治疗的药物的非临床评价行业指南, tagList=[TagDto(tagId=644, tagName=骨质疏松症)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=21067, categoryName=梅斯医学-骨质疏松网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3021, appHits=315, showAppHits=3, pcHits=1688, showPcHits=1338, likes=124, shares=7, comments=4, approvalStatus=1, publishedTime=Thu Oct 31 08:57:46 CST 2019, publishedTimeString=2019-10-31, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=fbzhang, createdTime=Thu Oct 31 08:57:46 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 16:16:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=骨质疏松症：治疗的药物的非临床评价行业指南（FDA）)])
骨质疏松症：治疗的药物的非临床评价行业指南（FDA）
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214747, encodeId=8b0b1214e479f, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:52:34 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894433, encodeId=0152894433db, content=参考一下 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ba5428984, createdName=ms4000001721349783, createdTime=Sun Oct 25 23:25:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809855, encodeId=f458809855d2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:06:20 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2022-04-26 su_yi_fei

    看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214747, encodeId=8b0b1214e479f, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:52:34 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894433, encodeId=0152894433db, content=参考一下 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ba5428984, createdName=ms4000001721349783, createdTime=Sun Oct 25 23:25:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809855, encodeId=f458809855d2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:06:20 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-10-25 ms4000001721349783

    参考一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214747, encodeId=8b0b1214e479f, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:52:34 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894433, encodeId=0152894433db, content=参考一下 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ba5428984, createdName=ms4000001721349783, createdTime=Sun Oct 25 23:25:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809855, encodeId=f458809855d2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:06:20 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-17 ms5000002046462755

    好

    0

相关指南

ASCO临床实践指南：非转移成人癌症幸存者骨质疏松症的管理 2019

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2019-09-27

中国定量CT( QCT) 骨质疏松症诊断指南（2018）

中国老年学和老年医学学会(CAGG,China Association of Gerontology and Geriatrics) 骨质疏松分会 · 2019-06-20

2019 共识声明：骨转换标志物用于亚太地区骨质疏松症治疗短期监测

亚太地区骨科专家小组（统称） · 2019-03-20

2019 TES临床实践指南：女性绝经后骨质疏松症的药物治疗

美国内分泌学会(TES,The Endocrine Society) · 2019-03-25

2018 法国绝经后骨质疏松症的管理建议（更新版）

法国风湿病学学会(SFR,French Society for Rheumatology) · 2018-04-11

《2017 年ACR 糖皮质激素性骨质疏松症防治指南》解读·

暂未更新 · 2018-01-20